Deverra
- Business Model
- B2B
- Website
- deverratx.com
About
Develops off-the-shelf cellular immunotherapies for cancer and infectious diseases
Summary
Deverra is a Biotech company.
Similar Companies
BeiGeneIPO
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Cambridge, United States10001+Biotech, Oncology
Corporate Round·$2.8B·Jan 2020
Sana BiotechnologyIPO
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Seattle, United States201–500Biotech, Healthcare
Series D·$1.4B·Jun 2020

Abogen Biosciences
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Suzhou, China201–500Biotech, mRNA Therapeutics
Extension Round·$1.3B·Nov 2021
Alnylam PharmaceuticalsIPO
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Cambridge, United States1001–5000Biotech, Genomics
Corporate Round·$1.0B·Apr 2020
ArsenalBio
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
San Francisco, United States201–500Biotech, Life Sciences
Series C·$955.0M·Sep 2024
Lyell ImmunopharmaIPO
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
South San Francisco, United States201–500Biotech, Healthcare
Venture Round·$884.0M·Jul 2025